Recombinant Human ACVR2A/Activin RIIA Protein, N- His & GST

ACVR2A, also known as Activin Receptor Type IIA, is a crucial component of the TGF-β superfamily of receptors, playing a significant role in various biological processes, including embryonic development, cell proliferation, and differentiation. The receptor is primarily involved in mediating the effects of activin and myostatin, making it essential for muscle growth regulation and various cellular functions. Abnormalities in ACVR2A signaling have been linked to several pathological conditions, such as cancer, muscle wasting, and fibrotic diseases. Consequently, understanding the structure and function of ACVR2A is vital for developing targeted therapies. Recombinant ACVR2A proteins facilitate the exploration of its biological roles and interactions with ligands, providing insights into its mechanisms in cellular signaling pathways. These proteins are valuable tools in both basic and translational research, helping to elucidate the receptor's role in disease and identify potential therapeutic targets. By employing recombinant techniques, researchers can produce active, high-purity ACVR2A proteins, making them essential for studying receptor dynamics, ligand binding affinities, and downstream signaling events. The development of ACVR2A recombinant proteins thus holds promise for advancing our understanding of its biological functions and therapeutic implications, particularly in muscle-related disorders and cancers, where modulating its activity might offer novel intervention strategies.